Protagonist Therapeutics, Inc. (PTGX)
| Market Cap | 6.46B +130.1% |
| Revenue (ttm) | 74.06M -64.4% |
| Net Income | -114.71M |
| EPS | -1.79 |
| Shares Out | 64.31M |
| PE Ratio | n/a |
| Forward PE | 29.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 310,321 |
| Open | 102.74 |
| Previous Close | 102.21 |
| Day's Range | 99.43 - 103.71 |
| 52-Week Range | 45.28 - 107.84 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 118.69 (+18.22%) |
| Earnings Date | May 5, 2026 |
About PTGX
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class or... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price target is $118.69, which is an increase of 18.22% from the latest price.
News
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics price target raised to $130 from $125 at Citi
Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $130 from $125 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
Protagonist Therapeutics price target raised to $137 from $120 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Protagonist Therapeutics (PTGX) to $137 from $120 and keeps an Outperform rating on the shares. Protagonist Therapeutics is expecte...
Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $97 and keeps a Neutral rating on the shares. The price target increase is driven mainly…
Protagonist Therapeutics management to meet virtually with Clear Street
Virtual Meeting to be held on May 12-13 hosted by Clear Street.
Protagonist Therapeutics participates in a conference call with JPMorgan
Conference call with management will be held on May 6 at 2 pm hosted by JPMorgan.Webcast Link
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible ...
Protagonist Therapeutics Earnings release: Q1 2026
Protagonist Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Protagonist Therapeutics Quarterly report: Q1 2026
Protagonist Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide
Protagonist Therapeutics (PTGX) announced that it has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under its worldwide license and collaboration agreement with…
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 millio...
Protagonist Therapeutics Proxy statement: Proxy filing
Protagonist Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Protagonist Therapeutics Proxy statement: Proxy filing
Protagonist Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accor...
Protagonist Therapeutics price target raised to $121 from $110 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $121 from $110 and keeps a Buy rating on the shares. The firm is citing strong…
Protagonist Therapeutics price target raised to $121 from $110 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $121 from $110 and keeps a Buy rating on the shares. Following J&J’s (JNJ) commentary on…
Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on Protagonist Therapeutics (PTGX) to $116 from $104 and keeps a Buy rating on the shares. Following management meetings, the…
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results fur...
Protagonist price target raised to $110 from $107 at Leerink
Leerink analyst Faisal Khurshid raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $107 and keeps an Outperform rating on the shares. The firm is “impressed” with…
Protagonist Therapeutics price target raised to $120 from $112 at Citizens
Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $120 from $112 and keeps an Outperform rating on the shares. The firm says Icotyde’s approval represents a “meaningful…
Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $112 from $100 and keeps an Outperform rating on the shares. The firm believes the FDA approval of Icotyde…
Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Protagonist Therapeutics (PTGX) to $106 from $95 and keeps an Overweight rating on the shares after the company received FDA…
Protagonist Therapeutics price target raised to $125 from $115 at Citi
Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $125 from $115 and keeps a Buy rating on the shares. The views the FDA approval of Icotyde as…
Protagonist Therapeutics price target raised to $119 from $113 at Barclays
Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $119 from $113 and keeps an Overweight rating on the shares. The FDA approved Icotyde for patients with psoriasis…
Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $104 from $91 and keeps a Buy rating on the shares following the FDA approval of icotrokinra for…